Enanta Pharmaceuticals (ENTA) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $23.8 million.
- Enanta Pharmaceuticals' Accumulated Depreciation & Amortization fell 495.87% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year decrease of 495.87%. This contributed to the annual value of $23.8 million for FY2025, which is 495.87% down from last year.
- According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Accumulated Depreciation & Amortization is $23.8 million, which was down 495.87% from $22.5 million recorded in Q2 2025.
- Enanta Pharmaceuticals' Accumulated Depreciation & Amortization's 5-year high stood at $25.2 million during Q2 2024, with a 5-year trough of $18.9 million in Q3 2021.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $22.5 million (2025), whereas its average is $22.5 million.
- In the last 5 years, Enanta Pharmaceuticals' Accumulated Depreciation & Amortization soared by 2074.77% in 2021 and then tumbled by 1067.35% in 2025.
- Enanta Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $18.9 million in 2021, then grew by 15.49% to $21.9 million in 2022, then grew by 8.63% to $23.7 million in 2023, then decreased by 15.23% to $20.1 million in 2024, then rose by 18.26% to $23.8 million in 2025.
- Its Accumulated Depreciation & Amortization was $23.8 million in Q3 2025, compared to $22.5 million in Q2 2025 and $21.3 million in Q1 2025.